PML-RARα and Its Phosphorylation Regulate PML Oligomerization and HIPK2 Stability

被引:15
|
作者
Shima, Yutaka [1 ]
Honma, Yuki [1 ]
Kitabayashi, Issay [1 ]
机构
[1] Natl Canc Ctr, Div Hematol Malignancy, Chuo Ku, Tokyo 1040045, Japan
关键词
ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; RETINOID-X-RECEPTOR; T(15-17) TRANSLOCATION; TRANSCRIPTION FACTORS; NB4; CELLS; ACID; DIFFERENTIATION; DOMAINS; ACTIVATION;
D O I
10.1158/0008-5472.CAN-12-3814
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The PML gene is frequently fused to the retinoic acid receptor alpha (RAR alpha) gene in acute promyelocytic leukemia (APL), generating a characteristic PML-RAR alpha oncogenic chimera. PML-RAR alpha disrupts the discrete nuclear speckles termed nuclear bodies, which are formed in PML, suggesting that nuclear body disruption is involved in leukemogenesis. Nuclear body formation that relies upon PML oligomerization and its stabilization of the hypoxia-inducible protein kinase (HIPK)-2 is disrupted by expression of the PML-RAR alpha chimera. Here, we report that disruption of nuclear bodies is also mediated by PML-RAR alpha inhibition of PML oligomerization. PKAmediated phosphorylation of PML-RAR alpha blocked its ability to inhibit PML oligomerization and destabilize HIPK2. Our results establish that both PML oligomerization and HIPK2 stabilization at nuclear bodies are important for APL cell differentiation, offering insights into the basis for the most common prodifferentiation therapies of APL used clinically. (C) 2013 AACR.
引用
收藏
页码:4278 / 4288
页数:11
相关论文
共 50 条
  • [11] PML-RARα enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway
    Huang, Ying
    Hou, Jia-Kai
    Chen, Ting-Ting
    Zhao, Xu-Yun
    Yan, Zhao-Wen
    Zhang, Jing
    Yang, Jie
    Kogan, Scott C.
    Chen, Guo-Qiang
    AUTOPHAGY, 2011, 7 (10) : 1132 - 1144
  • [12] Comparison of laboratory characteristics and clinical prognosis of APL with negative and positive PML-RARα gene
    Cao, Xinran
    Guo, Diyuan
    Zhang, Bin
    MEDICINE, 2024, 103 (47) : e40671
  • [13] The PML-RARα fusion protein and targeted therapy for acute promyelocytic leukemia
    Jing, YK
    LEUKEMIA & LYMPHOMA, 2004, 45 (04) : 639 - 648
  • [14] Mutant AF-2 domain of PML-RAR alpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RAR alpha and its down-regulation in acute promyelocytic leukemia
    Kitamura, K
    Kiyoi, H
    Yoshida, H
    Saito, H
    Ohno, R
    Naoe, T
    LEUKEMIA, 1997, 11 (11) : 1950 - 1956
  • [15] Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53
    Sung, Ki Sa
    Lee, Yun-Ah
    Kim, Eui Tae
    Lee, Seung-Rock
    Ahn, Jin-Hyun
    Choi, Cheol Yong
    EXPERIMENTAL CELL RESEARCH, 2011, 317 (07) : 1060 - 1070
  • [16] PML-RARα inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia
    Ohnishi, Kazunori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (05) : 313 - 317
  • [17] Chromatin topology reorganization and transcription repression by PML-RARα in acute promyeloid leukemia
    Wang, Ping
    Tang, Zhonghui
    Lee, Byoungkoo
    Zhu, Jacqueline Jufen
    Cai, Liuyang
    Szalaj, Przemyslaw
    Tian, Simon Zhongyuan
    Zheng, Meizhen
    Plewczynski, Dariusz
    Ruan, Xiaoan
    Liu, Edison T.
    Wei, Chia-Lin
    Ruan, Yijun
    GENOME BIOLOGY, 2020, 21 (01)
  • [18] PML-RARα inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia
    Kazunori Ohnishi
    International Journal of Clinical Oncology, 2007, 12 : 313 - 317
  • [19] The Organic Arsenic Derivative GMZ27 Induces PML-RARα-Independent Apoptosis in Myeloid Leukemia Cells
    Cheng, Xaodong
    Quintas-Cardama, Alfonso
    Golemovic, Mirna
    Zingaro, Ralph
    Gao, Ming-Zhang
    Freirech, Emil J.
    Andreeff, Michael
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    ANTICANCER RESEARCH, 2012, 32 (07) : 2871 - 2880
  • [20] MER1, a novel organic arsenic derivative, has potent PML-RARα- independent cytotoxic activity against leukemia cells
    Golemovic, Mirna
    Quintas-Cardama, Alfonso
    Manshouri, Taghi
    Orsolic, Nada
    Duzkale, Hatice
    Johansen, Mary
    Freireich, Emil J.
    Kantarjian, Hagop
    Zingaro, Ralph A.
    Verstovsek, Srdan
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (04) : 402 - 412